Medical devices, healthcare technology and the business of care
PMA approval · P100034

NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT

Novocure, GmbH · Decision date Apr 8, 2011

FDA DECISIONP100034

What did the FDA approve?

FDA records P100034 as an original PMA application. The recorded decision is approval, dated Apr 8, 2011.

FDA approval order statement

APPROVAL FOR THE NOVOTTF-100A SYSTEM. THE DEVICE IS INDICATED FOR TREATMENT OF ADULT PATIENTS (22 YEARS OF AGE OR OLDER) WITH HISTOLOGICALLY- CONFIRMED GLIOBLASTOMA MULTIFORME, FOLLOWING HISTOLOGICALLY- OR RADIOLOGICALLY- CONFIRMED RECURRENCE IN THE SUPRATENTORIAL REGION OF THE BRAIN AFTER RECEIVING CHEMOTHERAPY. THE DEVICE IS INTENDED TO BE USED AS A MONOTHERAPY, AND IS INTENDED AS AN ALTERNATIVE TO STANDARD MEDICAL THERAPY FOR GBM AFTER SURGICAL AND RADIATION OPTIONS HAVE BEEN EXHAUSTED.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Apr 8, 2011

FDA source record

Regulatory record facts

Identifier
P100034
Regulatory pathway
Premarket approval application
Product code
NZK
Decision code
APPR
Decision date
Apr 8, 2011
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, low electric field, tumor treatment.

Product code
NZK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P100034 received

    Application receipt date recorded by FDA.

  2. P100034 · FDA decision

    APPR

  3. P100034/S046 · Related supplement

    Optune HFE Transducer Arrays

  4. P100034/S045 · Related supplement

    Novocure GmbHs Optune Gio

Timeline entries are records held by MedtechLedger for P100034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100034

Product / regulatory recordCompanyPathwayDecision dateSource
Novocure, GmbHPMA supplementSep 16, 2026FDA
Novocure, GmbHPMA supplementSep 18, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Novocure, GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Neuhofstrasse 21, Baar, 6340

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records